PRTA Prothena Corp Public Ltd Co

  1. Stocks
  2. Healthcare
  3. NASDAQ: PRTA

Price (delayed)

$47.07

Market cap

$2.47B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.47

Enterprise value

$1.77B

Prothena Corporation plc is a late-stage clinical company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapeutics with the potential to change the course of devastating ...

Highlights
The company's equity has surged by 54% QoQ and by 33% YoY
Prothena's debt has decreased by 47% YoY and by 19% from the previous quarter
The quick ratio has increased by 45% since the previous quarter but it has declined by 18% year-on-year
Prothena's revenue has plunged by 73% YoY
The company's gross profit has shrunk by 73% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.prothena.com/
Peers: ALKS ALNY AMRN

Key stats

What are the main financial stats of PRTA
Market
Shares outstanding
52.56M
Market cap
$2.47B
Enterprise value
$1.77B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.66
Price to sales (P/S)
41.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.84
Earnings
Revenue
$53.91M
EBIT
-$125.61M
EBITDA
-$118.86M
Free cash flow
-$109.29M
Per share
EPS
-$2.47
Free cash flow per share
-$2.31
Book value per share
$12.86
Revenue per share
$1.14
TBVPS
$16
Balance sheet
Total assets
$758.04M
Total liabilities
$135.99M
Debt
$6.47M
Equity
$622.04M
Working capital
$668.95M
Liquidity
Debt to equity
0.01
Current ratio
14.34
Quick ratio
14.17
Net debt/EBITDA
5.92
Margins
EBITDA margin
-220.5%
Gross margin
100%
Net margin
-217%
Operating margin
-244.1%
Efficiency
Return on assets
-19.1%
Return on equity
-25%
Return on invested capital
-1,161%
Return on capital employed
-17.7%
Return on sales
-233%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

PRTA stock price

How has the Prothena stock price performed over time
Intraday
-2.08%
1 week
-2.49%
1 month
-13.66%
1 year
24.43%
YTD
-21.88%
QTD
-21.88%

Financial performance

How have Prothena's revenue and profit performed over time
Revenue
$53.91M
Gross profit
$53.91M
Operating income
-$131.56M
Net income
-$116.95M
Gross margin
100%
Net margin
-217%
Prothena's net margin has soared by 93% from the previous quarter
The operating margin has soared by 92% since the previous quarter
Prothena's revenue has plunged by 73% YoY
The company's gross profit has shrunk by 73% YoY

Growth

What is Prothena's growth rate over time

Valuation

What is Prothena stock price valuation
P/E
N/A
P/B
3.66
P/S
41.36
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.84
The company's EPS rose by 28% QoQ
The company's equity has surged by 54% QoQ and by 33% YoY
PRTA's price to book (P/B) is 22% lower than its last 4 quarters average of 4.7 but 14% higher than its 5-year quarterly average of 3.2
PRTA's price to sales (P/S) is 90% lower than its 5-year quarterly average of 394.0 and 73% lower than its last 4 quarters average of 155.8
Prothena's revenue has plunged by 73% YoY

Efficiency

How efficient is Prothena business performance
The company's return on sales has surged by 93% QoQ
The ROE has increased by 32% from the previous quarter
Prothena's return on assets has increased by 30% QoQ
The ROIC has grown by 13% from the previous quarter

Dividends

What is PRTA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for PRTA.

Financial health

How did Prothena financials performed over time
The quick ratio has increased by 45% since the previous quarter but it has declined by 18% year-on-year
PRTA's current ratio is up by 38% since the previous quarter but it is down by 18% year-on-year
Prothena's debt is 99% less than its equity
Prothena's debt to equity has shrunk by 67% YoY and by 50% QoQ
The company's equity has surged by 54% QoQ and by 33% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.